Masimo Announces Eight of Top 10 U.S. Hospitals Now Use

IRVINE, CA--(Marketwired - Jul 31, 2013) - Masimo ( NASDAQ : MASI ) today announced that Masimo SET ^® pulse oximetry is now being used hospital-wide in eight of the top10 hospitals on the current U.S. News & World Report Best Hospitals Honor Roll (2013-2014).

Among the hospitals on the list: Brigham and Women's Hospital, Cleveland Clinic, The Johns Hopkins Hospital, Massachusetts General Hospital, Mayo Clinic, UCLA Medical Center, and UCSF Medical Center.

Masimo SET ^® pulse oximetry has been shown to virtually eliminate false alarms ¹ and increase a clinician's ability to detect life-threatening events ² -- helping to substantially contribute to improved patient outcomes and patient safety. The clinical accuracy of Masimo SET ^® pulse oximetry has also been shown to help clinicians significantly reduce retinopathy of prematurity ^3-5 , screen for critical congenital heart disease in newborns ^6-8 , reduce oxygen overdose ^{9, 10} and medical errors ^{11, 12} , and save lives in post-surgical floors, recovery ² , labor and delivery rooms ¹³ , and ICUs ¹⁴ .

More than 100 independent clinical studies have confirmed that Masimo SET ^® technology allows clinicians to accurately monitor blood oxygen saturation in the most challenging conditions, including patient movement and low peripheral perfusion. ¹⁵

"We are proud to call these great institutions, our customers; and, we will continue to do our best to serve not only these world-renowned clinical centers, but all of our caring clinical customers, so that they can serve their patients the best way possible," said Masimo Founder and CEO, Joe Kiani.

1. Shah N, Ragaswamy H, Govindugari K, Estanol L. "Performance of three new-generation pulse oximeters during motion and low perfusion in volunteers." Journal of Clinical Anesthesia . 2012 (10.1016/j.jclinane.2011.10.012) Available online here 2. Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology , February 2010, Vol. 112, Issue 2. Available online here 3. Chow L.C., Wright K.W., Sola A.; CSMC Oxygen Administration Study Group. "Can Changes in Clinical Practice Decrease the Incidence of Severe Retinopathy of Prematurity in Very Low Birth Weight Infants?" Pediatrics . 2003 Feb;111(2):339-45. 4. Clinical Practice and SpO ₂ Technology in the Prevention of ROP in VLBW Infants. Castillo AR, Deulofeut R, Sola A. Presented at Pediatric Academic Societies Annual Meeting May 5-8, 2007.  5. Oxygen as a neonatal health hazard: call for détente in clinical practice. Sola A., Rogido, Marta, Deulofeut, Richard. Acta Paediatrica 2007; 96:801-812. 6. de Wahl Granelli A, Wennergren M, Sandberg K, et al. Impact of pulse oximetry screening on detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ 2009; 338: a3037. 7. Noninvasive Peripheral Perfusion Index as a Possible Tool for Screening for Critical Left Heart Obstruction. Granelli, AD, Ostman-Smith, I. Acta Paediatrica 2007; 96:1455-1459. 8. Screening for Duct-Dependent Congenital Heart Disease with Pulse Oximetry: A Critical Evaluation of Strategies to Maximize Sensitivity. Granelli AD, Mellander M, Sunnegardh J,Sandberg K, Ostman-Smith I. Acta Paediatr 2005; 94:1590-6. 9. Avoiding Hyperoxemia During Neonatal Resuscitation: Time to Response to Different SpO ₂ Monitors. Baquero H, Alviz R, Sola A. Presented at Pediatric Academic Societies Annual Meeting May 5-8, 2007. A 10. More Reliable Oximetry Reduces the Frequency of Arterial Blood Gas Analyses and Hastens Oxygen Weaning after Cardiac Surgery. Durbin CG, Rostow SK. Crit Care Med 2002; 30(8): 1735-1740 11. Advantages of New Technology Pulse Oximetry with Adults in Extremis. Durbin CG, Rostow SK. Anesth Analg 2002; 94: S81-S83 12. Pulse Oximetry Performance Can Affect Caregiver Time Utilization. Durbin CG, Rostow SK. Anesthesiology 2000;93(3A): A556. 13. Baquero H, Alviz R, Castillo A, Neira F, Sola A. "Avoiding Hyperoxemia During Neonatal Resuscitation: Time To Response Of Different SpO2 Monitors." Acta Paed April 2011 Vol. 100, Issue 4, pp 515-518. Published online here 14. Goldstein MR, Martin GI, Sindel BD, Furman GI, Ochikubo C, Yand L. SatSeconds Alarm Management Misses Short Desaturations Common to Periodic Breathing and Infantile Apnea. Pediatric Research 2001;49(4):400A/2296. 15. Full Citation List of All Available Clinical Studies Featuring Masimo: http://www.masimo.com/cpub/clinical-masimo-set.htm

About Masimo Masimo ( NASDAQ : MASI ) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET ^® , which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET ^® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET ^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb ^® ), oxygen content (SpOC™), carboxyhemoglobin (SpCO ^® ), methemoglobin (SpMet ^® ), and Pleth Variability Index (PVI ^® ), in addition to SpO ₂ , pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com .

Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo SET provides real-time results for all patients to help clinicians to more rapidly assess, diagnose, and treat every patient; risks related to our assumptions regarding the repeatability of clinical results; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission (" SEC "), which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.